TKNO Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals has a net margin of -61.73% compared to Alpha Teknova's net margin of -49.65%. Alpha Teknova's return on equity of -31.69% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Alpha Teknova has a consensus price target of $10.67, signalling upside risk potential of 111.13%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 39.8%. Given that Alpha Teknova has higher upside potential than NovaBay Pharmaceuticals, analysts believe Alpha Teknova is more attractive than NovaBay Pharmaceuticals.

Alpha Teknova has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.726, suggesting its less volatile than the S&P 500 by 27.363%.

Alpha Teknova has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alpha Teknova pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Alpha Teknova quarterly revenues are $9.3M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Alpha Teknova's net income of -$5.7M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Alpha Teknova's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alpha Teknova is 6.45x versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -61.73% compared to Alpha Teknova's net margin of -2357.27%. Alpha Teknova's return on equity of -31.69% beat Palatin Technologies's return on equity of --.

Alpha Teknova has a consensus price target of $10.67, signalling upside risk potential of 111.13%. On the other hand Palatin Technologies has an analysts' consensus of $7.00 which suggests that it could grow by 957.24%. Given that Palatin Technologies has higher upside potential than Alpha Teknova, analysts believe Palatin Technologies is more attractive than Alpha Teknova.

Alpha Teknova has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.793, suggesting its less volatile than the S&P 500 by 20.66%.

Alpha Teknova has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alpha Teknova pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Alpha Teknova quarterly revenues are $9.3M, which are larger than Palatin Technologies quarterly revenues of $350K. Alpha Teknova's net income of -$5.7M is lower than Palatin Technologies's net income of -$2.4M. Notably, Alpha Teknova's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alpha Teknova is 6.45x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -61.73% compared to Alpha Teknova's net margin of --. Alpha Teknova's return on equity of -31.69% beat Theriva Biologics's return on equity of --.

Alpha Teknova has a consensus price target of $10.67, signalling upside risk potential of 111.13%. On the other hand Theriva Biologics has an analysts' consensus of $6.00 which suggests that it could grow by 426.32%. Given that Theriva Biologics has higher upside potential than Alpha Teknova, analysts believe Theriva Biologics is more attractive than Alpha Teknova.

Alpha Teknova has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.159, suggesting its more volatile than the S&P 500 by 15.945%.

Alpha Teknova has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alpha Teknova pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Alpha Teknova quarterly revenues are $9.3M, which are larger than Theriva Biologics quarterly revenues of --. Alpha Teknova's net income of -$5.7M is lower than Theriva Biologics's net income of -$4.4M. Notably, Alpha Teknova's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alpha Teknova is 6.45x versus 0.63x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.

Zevra Therapeutics has a net margin of -61.73% compared to Alpha Teknova's net margin of -296.76%. Alpha Teknova's return on equity of -31.69% beat Zevra Therapeutics's return on equity of -208.85%.

Alpha Teknova has a consensus price target of $10.67, signalling upside risk potential of 111.13%. On the other hand Zevra Therapeutics has an analysts' consensus of $21.63 which suggests that it could grow by 175.48%. Given that Zevra Therapeutics has higher upside potential than Alpha Teknova, analysts believe Zevra Therapeutics is more attractive than Alpha Teknova.

Alpha Teknova has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Zevra Therapeutics has a beta of 1.977, suggesting its more volatile than the S&P 500 by 97.719%.

Alpha Teknova has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zevra Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alpha Teknova pays -- of its earnings as a dividend. Zevra Therapeutics pays out -- of its earnings as a dividend.

Alpha Teknova quarterly revenues are $9.3M, which are smaller than Zevra Therapeutics quarterly revenues of $12M. Alpha Teknova's net income of -$5.7M is higher than Zevra Therapeutics's net income of -$35.7M. Notably, Alpha Teknova's price-to-earnings ratio is -- while Zevra Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alpha Teknova is 6.45x versus 15.37x for Zevra Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.